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Abstract 
Chronic inflammation has emerged as a key factor that contributes to some common chronic 
diseases and reduces lifespan. Studies have identified multiple types of chronic inflammation ranging 
from autoimmune disease, which attacks specific tissues, to autoinflammatory diseases, which cause 
low-grade systemic inflammation and contribute to several common chronic diseases. This article 
highlights new perspectives on the role of chronic inflammation in cardiovascular disease. Such 
information is being leveraged to develop new treatment strategies for cardiovascular disease and 
may inform how periodontal disease influences cardiovascular disease. 
<PE-FRONTEND> 
Chronic Inflammation as a Factor in Chronic Diseases and Reduced Lifespan 
A major change in the understanding of chronic inflammatory diseases occurred in the late 1990’s. 
Fundamental to this change was research focused on the association between levels of low-grade 
systemic inflammation and cardiovascular disease (CVD) clinical outcomes.1-5 These studies used 
high sensitivity C-reactive protein (hsCRP) analysis of blood samples as the indicator of systemic 
inflammation. CRP is one component of the acute phase responses that are produced by the liver in 
response to circulating cytokines, most commonly interleukin-6 (IL-6), IL-1β, and tumor necrosis 
factor alpha (TNFα). The concentration of hsCRP in the blood is an effective indicator of circulating 
pro-inflammatory cytokines arising from any inflamed tissue at the time of hsCRP measurement. 
Most hsCRP studies focused on prediction of cardiovascular disease outcomes in response to 
interventions that reduced inflammation, as measured by changes in hsCRP.  
Low density lipoprotein cholesterol (LDL-C) is accepted as a major causal factor for CVD and 
determinant of atherosclerotic events, although several modifying risk factors certainly influence 
disease expression. The systemic inflammation studies in recent years challenged the concept that 
CVD was primarily caused by LDL-C driven lipid accumulation on the arterial wall, which ultimately 
produced symptoms that required medication, surgical interventions, or both.6 The early 
inflammation studies in CVD intervention provided evidence that reducing systemic inflammation 
was as protective against recurrent or initial major atherosclerotic events as was lowering LDL-C.3,4,7 
During the same period, evidence emerged, primarily from genetic studies, to support the causality 
of another lipid factor, lipoprotein(a) [Lp(a)] in CVD.8-11 The LPA gene, encoding Lp(a), is highly 
polymorphic, and its expression determines plasma levels of Lp(a) that vary among populations. 
Consequently, and in contrast to LDL-C, Lp(a) blood levels are not influenced by diet, exercise, or 
statins. 
In parallel to the inflammation clinical trials, researchers were identifying a key role for IL-1β as a 
major driver of vascular inflammation and trigger of atherosclerotic events.5,6,12-14  In a clinical study 
of patients with CVD, the risk of coronary artery disease increased with blood levels of Lp(a) that 
were above the median, but primarily in patients with IL1B genetic patterns that lead to high 
expression of IL-1β protein. The subjects without genetic patterns that led to high IL-1β levels had 
minimal increased risk of coronary artery disease regardless of elevated Lp(a) level.9,10,15-17 
On the basis of many studies implicating systemic inflammation and the role of IL-1β in CVD,18-22 a 
10,000-person randomized controlled trial tested if blocking inflammation with canakinumab, an 
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antibody specifically targeting IL-1β, reduced the risk of cardiovascular events in a high-risk patient 
population.5,22 The results were striking. Not only did blocking inflammation reduce the incidence of 
recurrent major cardiovascular events, but it also reduced the number of hospitalizations in patients 
with heart failure,23 the incidence of lung cancer,24 and the occurrence of major renal events in 
patients with chronic kidney disease.25 
Another study implicated chronic systemic inflammation as a risk factor that prevents healthy aging. 
The “Hawaii Lifespan Study” is a longitudinal study of Japanese-American men born and living in 
Hawaii.26 Survival analysis of this cohort of men found that indicators of low-grade chronic 
inflammation, such as higher concentrations of circulating fibrinogen or increased numbers of white 
blood cells, were associated with reduced survival. This chronic inflammation was one of only 7 
primary factors that prevented healthy aging. Thus, chronic inflammation is a key factor that 
contributes to both chronic disease risk and healthy aging. 
Types of Chronic Inflammatory Disease 
Although the CVD studies increased awareness of chronic inflammatory diseases, such diseases are 
not a single entity. The most prevalent chronic inflammatory diseases, obesity and periodontitis, 
involve chronic continuing challenges. The chronic inflammation of obesity is driven by an 
overnutrition challenge, and a chronic interproximal bacterial challenge leads to most cases of 
periodontitis. Substantial new understanding about autoinflammatory and autoimmune diseases has 
emerged due in large part to classification of such diseases as a biologic continuum (Figure 1).27,28 
The classic chronic inflammatory disease is often activated by an autoimmune process, such as in 
rheumatoid arthritis. These diseases have high levels of systemic inflammation, with circulating CRP 
concentrations that often exceed 10 mg/L.29 Not only is there autoimmune destruction of local 
tissues, but there is also tissue damage that results from secondary inflammation caused by the 
autoimmune attack. There are more than 80 autoimmune diseases, which exhibit great variation 
among patients in terms of their severity. In all of these, the underlying issue is dysregulated 
immune tolerance to one’s own tissues and subsequent inflammatory damage to local tissues. TNFα 
blocking agents, such as etanercept, have been very effective with several autoimmune diseases 
including rheumatoid arthritis, Crohn’s Disease, psoriasis, and others.30 
Autoinflammatory diseases represent another dimension of chronic inflammatory diseases. They 
were originally identified in patients that had unpredictable flares that produced symptoms, 
including fever, skin rashes, or joint swelling that were known to be initiated by innate immune 
mechanisms. Clinicians recognized that these presentations were rare and were ultimately identified 
as being caused by genetic mutations in biological mechanisms that regulated the innate immune 
response. It became clear that these rare autoinflammatory diseases were not autoimmune diseases 
involving antibodies that attacked the patient’s healthy body tissues. 
Some of these autoinflammatory diseases are rare monogenic diseases and others are quite 
common. Among the rare monogenic diseases are FMF (Familial Mediterranean Fever), NOMID 
(Neonatal Onset Multisystem Inflammatory Disease), and DIRA (Deficiency of Interleukin-1 Receptor 
Antagonist). These diseases are associated with rare mutations in inflammasome genes that lead to 
a dysregulated active caspase-1 that converts pro-IL-1β to active IL-1β. Such mutations result in high 
levels of IL-1β released to cause the symptom patterns associated with the rare monogenic 
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autoinflammatory diseases. Anti-TNFα drugs are less effective for the autoinflammatory diseases as 
opposed to the autoimmune diseases.  
In contrast to the rare autoinflammatory diseases, there is emerging recognition and interest in 
more prevalent chronic inflammatory diseases that are in part driven by an imbalance of key 
cytokines, including IL-1β and IL-6, that drive innate immunity. These more common diseases driven 
by an imbalance of innate immunity do not display the intense episodes of acute inflammation, as 
described above for rare autoinflammatory diseases.30 Both the rare forms of autoinflammatory 
disease and the more common forms are defined by increased inflammation involving cytokines of 
the innate immune system, more specifically IL-1β.  
Atherosclerotic cardiovascular disease is the most well-studied common disease in which increased 
risk for major clinical events is found in patients with persistent elevations of systemic inflammation, 
as defined by blood hsCRP, despite various drugs that produce substantial reductions in LDL 
cholesterol levels.31 The systemic inflammatory challenge in chronic diseases can be from 
dysregulated metabolism as occurs in cancer and metabolic disorders, genetic factors, respiratory 
and skin irritants, and unresolved infections. These common autoinflammatory diseases are typically 
associated with excessive production of cytokines that activate amplifying cascades, in particular IL-
1β or IL-6.13,31,32 It is well established that once released, IL-1β self-activates its own gene expression 
through the IL-1 receptor I. The auto-stimulation has been shown in some clinical situations to be 
the result of an imbalance between the IL-1β agonist and the natural antagonist IL-1Ra, which has 
been demonstrated in Type 2 diabetes33 and in progressive knee osteoarthritis.34  The pathologic 
outcomes arise from amplifying cascades driven by cytokine-activated pathways.  
A newer concept in chronic inflammatory diseases is that some common conditions do not have 
overt characteristics of inflammation and generally do not respond predictably to non-specific anti-
inflammatory drugs,5,21,31,35 yet these conditions have an essential inflammatory component that 
drives the pathology. 5,23,24,36 These are often common diseases in which low-grade chronic 
inflammation may be evident, but disease-initiating factors become the focus of preventing or 
managing the disease. Examples include diet-influenced saturated fats or high blood pressure as 
initiating factors in CVD; 5,6 smoking in lung cancer; 24 and physical trauma to a joint in 
osteoarthritis.34,37 In those examples of common chronic diseases, there are activating factors that 
trigger inflammation control points, such as IL-1β, that drive multiple cascades that amplify or 
resolve inflammation at various stages. The inflammatory response is essential to health but 
depends on tightly controlled regulation. If the inflammation activators are too potent or prolonged, 
the downstream inflammatory mediators that make prostaglandins, vascular adhesion molecules, 
chemotaxins, hematopoietic factors, lymphocyte and tissue cell growth factors, and other cytokines, 
such as IL-6 and IL-8, can lead to disease and tissue damage. The evolving concepts of common 
autoinflammatory diseases are well characterized by extensive work on the role of low-grade 
systemic inflammation in cardiovascualr disease events.1,4,5  
These downstream inflammatory mediators then drive damage to arterial vessels in CVD, amplify 
destruction of pulmonary tissue in lung cancer, and destroy both connective tissue and bone in 
osteoarthritis. These common diseases with a chronic inflammatory component generally do not 
have an autoimmune component and are associated with low-grade circulating CRP (less than 10 
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mg/L). Indeed, in CVD, the increased risk for cardiovascular events has been associated with hsCRP 
levels exceeding 2 mg/L.36   
Common chronic diseases also have an imbalance in inflammation that is evident as elevated hsCRP  
and, combined with inflammation activators, such as lipoprotein(a) or low-density lipoprotein 
cholesterol, produce a low-grade chronic inflammation. Such conditions have been recently 
validated in a randomized controlled clinical trial involving an IL-1β inhibitor (canakinumab).5 Thus, 
chronic inflammation can contribute to common chronic diseases, such as CVD,5 cancer,24 and 
chronic kidney disease.25 Both a secondary inflammatory response to tissue injury or the presence of 
an autoinflammatory condition can contribute to common chronic diseases that impact healthy 
aging, quality of life, and ultimately lifespan. 
Targeting the Inflammatory Component of Cardiovascular Disease 
The evolution of observations and technologies that drove various concepts of pathogenesis of 
atherosclerosis since the 1800’s has been richly described by Libby and Hansson.6 The clinical 
evidence supports that at least two blood lipids, LDL-C and Lp(a), along with inflammatory 
mechanisms, produce atherosclerotic CVD that, in some individuals, results in Major Adverse 
Cardiovascular Events (MACE). 
Recent clinical trials demonstrated that PCSK9 inhibitors achieved dramatic lowering of LDL-C 
beyond that attainable with intensive statin therapy and, as a result, strongly enhanced prevention 
of recurrent MACE.38,39 An antisense drug targeting Lp(a) is also under investigation.40 However, it 
will be a few years before the results will show if this drug lowers Lp(a) sufficiently to reduce MACE. 
The development of MACE in individuals with elevated Lp(a) was conditional on the presence of an 
IL-1β genetic pattern that leads to high production of IL-1β protein.16,17 In high risk CVD patients, 
drugs that specifically block IL-1β, but not less specific anti-inflammatory drugs, reduced MACE.35  
With this appreciation of the role of inflammation as a key driver of CVD events, new treatment 
options have been and are being developed (Figure 2). These include blocking the lipids that trigger 
atherosclerosis and vascular inflammation. Such agents include inhibitors of PCSK9, a liver protein 
that promotes the degradation of LDL receptors which leads to higher cholesterol. The PCSK9 
inhibitors block degradation of LDL receptors which reduces blood cholesterol. Even in patients 
already taking statins, PCSK9 inhibitors have dramatically reduced LDL-cholesterol and the risk of 
cardiovascular disease events. 18,19 An antisense drug designed to specifically reduce Lp(a) is in Phase 
III clinical trials.40  
If the initiating factors are not reduced or the patient fails to respond to such treatments, MACE can 
be reduced by blocking the key drivers of arterial inflammation, most prominently IL-1β. IL-1β must 
be activated by molecular complexes called inflammasomes. Thus, there are several points at which 
IL-1β signaling can be inhibited: Drugs can target IL-1β itself, as with canakinumab,22,24 drugs can 
inhibit the assembly of the inflammasome to block processing and release of IL-1β, or drugs can 
inhibit the induction of IL-1β by either blocking the intracellular signaling pathway or by preventing 
activation of the receptors that initiate IL-1β expression.  
Implications for Treating Periodontal Disease 
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Much of the clinical focus has been on systemic inflammation as a contributor to chronic disease. 
However, chronic diseases can also contribute to systemic inflammation, thereby connecting 
multiple chronic diseases through an inflammatory component. These inflammatory diseases include 
periodontitis, type 2 diabetes, obesity, and others. Indeed, obesity and periodontitis are among the 
most prevalent chronic inflammatory diseases and are risk factors for other chronic diseases (Figure 
3).  
Although periodontitis, as with CVD, does not exhibit the classic signs of rare autoinflammatory 
diseases including unpredictable fevers, skin rashes, and joint damage, severe periodontitis is 
characterized by increased levels of IL-1β41-45 and CRP,46-48 which are consistent with other common 
autoinflammatory diseases.49 
In recent years, investigators have used large clinical databases to ask whether the presence of a 
specific disease that increases systemic inflammation also increases the risk for future cardiovascular 
disease or type 2 diabetes. One of the most impressive studies of this type used the UK clinical 
practice research database and identified more than 100,000 patients with diagnoses of specific 
types of chronic inflammatory diseases. They asked whether the presence of one or more of the 
chronic inflammatory diseases increased the risk for future coronary artery disease, stroke, or type II 
diabetes. They compared the frequency of these three diseases in individuals who had a chronic 
inflammatory disease and those that did not. There were greater than 370,000 individuals who had 
no prior history of chronic inflammatory diseases and served as the reference population.50 The 
investigators reported that individuals with a history of chronic inflammatory disease and increased 
systemic inflammation had a 30 to 35% greater incidence of coronary artery disease, stroke, or type 
2 diabetes compared to the reference group. 
The studies of inflammation in chronic disease, which have used hsCRP as the indicator, have 
revealed many factors that influence systemic inflammatory burden (Figure 3). These factors include 
ethnicity, gender, smoking, polymorphisms in genes involved in inflammation, diet, and other 
environmental factors. These factors increase systemic inflammatory burden, which then 
contributes to chronic diseases, including rheumatoid arthritis, Alzheimer’s disease, type 2 diabetes, 
coronary artery disease, obesity, and moderate to advanced periodontitis. The current challenge is 
identifying which individuals with chronic inflammatory diseases, such as periodontitis, have 
increased systemic inflammation that alters the course of other chronic diseases including 
cardiovascular disease and Type 2 diabetes. Systemic inflammation is a central player that connects 
periodontitis to multiple chronic diseases of aging. 
Conclusion 
Although there are many studies that show an independent association between moderate to 
severe periodontitis and coronary artery disease and strokes, there are no direct intervention 
studies that show treatment of specific cases of periodontitis reduce MACE. It is reasonable, 
however, to propose establishing salivary and blood biomarkers to objectively assess treatment 
outcomes of periodontitis that may include decreases in systemic biomarkers that have been shown 
to reduce both first and recurrent cardiovascular disease events as a first step. It is likely that the 
knowledge gained from the study of systemic inflammation in cardiovascular disease and other 
chronic diseases will inform new treatment strategies for periodontal disease.  
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 Figure 1. Inflammatory and autoimmune diseases are a continuum. Examples of rare monogenic 
autoinflammatory diseases include FMF (Familial Mediterranean Fever), CAPS (Cryopyrin-Associated 
Periodic Syndrome) and NOMID (Neonatal Onset Multisystem Inflammatory Disease). Examples of 
polygenic autoinflammatory diseases include Crohn’s disease, ulcerative colitis, psoriatic arthritis, 
CVD. Examples of polygenic autoimmune diseases include Systemic Lupus Erythematosus, Type 1 
diabetes, and rheumatoid arthritis. An example of a rare monogenic autoimmune disease is ALPS 
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Figure 2. New therapeutics from CVD studies that are poised to address common chronic 
inflammatory diseases. The left side represents drugs that specifically reduce CVD by targeting 
“residual cholesterol risk.” The right side represents drugs that could reduce CVD and other chronic 
diseases associated with increased systemic inflammation by reducing “residual inflammatory risk.” 
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Figure 3. Multiple factors contribute to an individual’s systemic inflammatory burden. Studies 
using hsCRP as an indicator of systemic inflammation revealed that gender, ethnicity, genetics, 
smoking, diet, and lifestyle contribute to systemic inflammatory burden. Systemic inflammatory 
burden contributes to multiple chronic diseases and diseases associated with aging. Periodontal 
disease and obesity are common inflammatory diseases. By causing systemic inflammation, chronic 
inflammatory diseases contributed to increased risk of other chronic diseases. [Credit: Heather 
McDonald, BioSerendipity, LLC] 
 
 
 
 
 
